Bruton tyrosine kinase inhibitors and cardiovascular adverse events
British Journal of Pharmacology · 30.07.2026
DOI: 10.1111/bph.70620 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Pharmacology, online erschienen am 30.07.2026. Verfasst von Massimiliano Camilli und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Sciences, A. Gemelli University Policlinic Foundation IRCCS, Rome, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias). Pharmacological differences in cardiotoxicity arise from binding mode and kinase selectivity profiles. First‐ and second‐generation covalent BTKi (ibrutinib, acalabrutinib, zanubrutinib) irreversibly target Cys481, leading to off‐target engagement of other kinases that regulate cardiac electrophysiology and also express homologous cysteine residues. In contrast, non‐covalent BTKi, such as pirtobrutinib, achieve selective and persistent BTK occupancy through Cys481‐independent interactions, substantially attenuating off‐target kinase inhibition and associated cardiotoxicity. Mechanistic insights support proactive baseline cardiovascular risk assessment and structured longitudinal surveillance to enable early detection, risk‐adapted management and sustained BTKi therapy. This mini‐review describes how such concepts apply to the issue of BTKi‐associated cardiovascular adverse events.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Sciences, A. Gemelli University Policlinic Foundation IRCCS, Rome, Italy.
- Department of Cardiovascular and Thoracic Sciences, Catholic University of the Sacred Heart, Rome, Italy.
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE) "G. D'Alessandro", University of Palermo, Palermo, Italy.
- Department of Medicine, University Campus Bio-Medico, Rome, Italy.
- Department of Medicine and Department of Science and Biotechnology, University and Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Zitieren
APA
Camilli, M., Madaudo, C., Salvatorelli, E., Minotti, G., & Menna, P. (2026). Bruton tyrosine kinase inhibitors and cardiovascular adverse events. British Journal of Pharmacology. https://doi.org/10.1111/bph.70620
Vancouver
Camilli M, Madaudo C, Salvatorelli E, Minotti G, Menna P. Bruton tyrosine kinase inhibitors and cardiovascular adverse events. British Journal of Pharmacology. 2026. doi:10.1111/bph.70620
BibTeX
@article{Camilli2026,
author = {Camilli, Massimiliano and Madaudo, Cristina and Salvatorelli, Emanuela and Minotti, Giorgio and Menna, Pierantonio},
title = {Bruton tyrosine kinase inhibitors and cardiovascular adverse events},
journal = {British Journal of Pharmacology},
year = {2026},
doi = {10.1111/bph.70620}
}
EUVIMED